anti-miR-21-SNA

anti-miR-21-SNA is an antisense oligonucleotide (ASO) synthesized from serinol nucleic acid (SNA) that targets microRNA-21 (miR-21). Developed by researchers at Nagoya University, this acyclic artificial nucleic acid therapeutic is designed to inhibit miR-21, which is aberrantly upregulated in cystic kidney diseases such as autosomal dominant polycystic kidney disease (ADPKD) and nephronophthisis. The SNA backbone provides high nuclease resistance and stable hybridization with target RNA without the need for toxic phosphorothioate modifications. In preclinical models, systemically administered anti-miR-21-SNA accumulates preferentially in the kidneys, where it suppresses renal cyst growth, improves renal function, and modulates pathways associated with mitochondrial metabolism, apoptosis, and tissue fibrosis.

Other names

anti-miR-21 oligonucleotideanti-miR21 oligonucleotideanti-miR 21 oligonucleotideanti-miR-21-serinol nucleic acidanti-miR21-serinol nucleic acidanti-miR 21-serinol nucleic acidanti-microRNA-21 oligonucleotide synthesized from serinol nucleic acidanti-microRNA21 oligonucleotide synthesized from serinol nucleic acidanti-microRNA 21 oligonucleotide synthesized from serinol nucleic acidanti-microRNA-21-serinol nucleic acidanti-microRNA21-serinol nucleic acidanti-microRNA 21-serinol nucleic acid